PH12012501944A1 - Parenteral pharmaceutical form which releases aromatse inhibitors and gestagens, for the treatment of endometriosis - Google Patents

Parenteral pharmaceutical form which releases aromatse inhibitors and gestagens, for the treatment of endometriosis

Info

Publication number
PH12012501944A1
PH12012501944A1 PH1/2012/501944A PH12012501944A PH12012501944A1 PH 12012501944 A1 PH12012501944 A1 PH 12012501944A1 PH 12012501944 A PH12012501944 A PH 12012501944A PH 12012501944 A1 PH12012501944 A1 PH 12012501944A1
Authority
PH
Philippines
Prior art keywords
endometriosis
treatment
pharmaceutical form
parenteral pharmaceutical
gestagens
Prior art date
Application number
PH1/2012/501944A
Other languages
English (en)
Inventor
Harri Jukarainen
Rudolf Knauthe
Henriikka Korolainen
Arto Pakkalin
Heinz Schmitz
Christine Talling
Original Assignee
Bayer Ip Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44021822&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PH12012501944(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bayer Ip Gmbh filed Critical Bayer Ip Gmbh
Publication of PH12012501944A1 publication Critical patent/PH12012501944A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/567—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in position 17 alpha, e.g. mestranol, norethandrolone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A61K31/569—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone substituted in position 17 alpha, e.g. ethisterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • A61K9/0036—Devices retained in the vagina or cervix for a prolonged period, e.g. intravaginal rings, medicated tampons, medicated diaphragms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Reproductive Health (AREA)
  • Engineering & Computer Science (AREA)
  • Gynecology & Obstetrics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
PH1/2012/501944A 2010-03-31 2011-03-28 Parenteral pharmaceutical form which releases aromatse inhibitors and gestagens, for the treatment of endometriosis PH12012501944A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE102010003494A DE102010003494A1 (de) 2010-03-31 2010-03-31 Parenterales Abgabesystem, das Aromatasehemmer und Gestagene freisetzt, für die Behandlung von Endometriose
PCT/EP2011/054737 WO2011120925A1 (de) 2010-03-31 2011-03-28 Parenterale arzneiform, die aromatasehemmer und gestagene freisetzt, für die behandlung von endometriose

Publications (1)

Publication Number Publication Date
PH12012501944A1 true PH12012501944A1 (en) 2017-01-06

Family

ID=44021822

Family Applications (1)

Application Number Title Priority Date Filing Date
PH1/2012/501944A PH12012501944A1 (en) 2010-03-31 2011-03-28 Parenteral pharmaceutical form which releases aromatse inhibitors and gestagens, for the treatment of endometriosis

Country Status (41)

Country Link
US (2) US20130131027A1 (https=)
EP (1) EP2552404B1 (https=)
JP (2) JP6012048B2 (https=)
KR (1) KR20130010047A (https=)
CN (1) CN103002873B (https=)
AR (1) AR080861A1 (https=)
AU (1) AU2011234587B2 (https=)
BR (1) BR112012024739A2 (https=)
CA (1) CA2794790A1 (https=)
CL (1) CL2012002722A1 (https=)
CO (1) CO6630125A2 (https=)
CR (1) CR20120493A (https=)
CU (1) CU20120145A7 (https=)
CY (1) CY1116187T1 (https=)
DE (1) DE102010003494A1 (https=)
DK (1) DK2552404T3 (https=)
DO (1) DOP2012000255A (https=)
EA (1) EA025582B1 (https=)
EC (1) ECSP12012176A (https=)
ES (1) ES2533101T3 (https=)
GT (1) GT201200267A (https=)
HR (1) HRP20150294T1 (https=)
IL (1) IL222056A (https=)
MA (1) MA34099B1 (https=)
ME (1) ME02159B (https=)
MX (1) MX2012011329A (https=)
MY (1) MY160353A (https=)
NZ (1) NZ602698A (https=)
PE (1) PE20130524A1 (https=)
PH (1) PH12012501944A1 (https=)
PL (1) PL2552404T3 (https=)
PT (1) PT2552404E (https=)
RS (1) RS53876B1 (https=)
SG (1) SG184111A1 (https=)
SI (1) SI2552404T1 (https=)
TN (1) TN2012000468A1 (https=)
TW (2) TW201632184A (https=)
UA (1) UA109655C2 (https=)
UY (1) UY33303A (https=)
WO (1) WO2011120925A1 (https=)
ZA (1) ZA201206869B (https=)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8633178B2 (en) 2011-11-23 2014-01-21 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US9301920B2 (en) 2012-06-18 2016-04-05 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US20130338122A1 (en) 2012-06-18 2013-12-19 Therapeuticsmd, Inc. Transdermal hormone replacement therapies
US10806697B2 (en) 2012-12-21 2020-10-20 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US20150196640A1 (en) 2012-06-18 2015-07-16 Therapeuticsmd, Inc. Progesterone formulations having a desirable pk profile
US10806740B2 (en) 2012-06-18 2020-10-20 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US11246875B2 (en) 2012-12-21 2022-02-15 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11266661B2 (en) 2012-12-21 2022-03-08 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US9180091B2 (en) 2012-12-21 2015-11-10 Therapeuticsmd, Inc. Soluble estradiol capsule for vaginal insertion
US10537581B2 (en) 2012-12-21 2020-01-21 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10471072B2 (en) 2012-12-21 2019-11-12 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10568891B2 (en) 2012-12-21 2020-02-25 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
EP3145489A1 (en) 2014-05-22 2017-03-29 TherapeuticsMD, Inc. Natural combination hormone replacement formulations and therapies
BR112017025097B1 (pt) * 2015-05-27 2021-05-11 Quest Diagnostics Investments Llc método para quantificação espectrométrica de massa de analitos extraídos de um dispositivo de microamostragem
US10328087B2 (en) 2015-07-23 2019-06-25 Therapeuticsmd, Inc. Formulations for solubilizing hormones
CN108430453B (zh) * 2015-12-21 2023-03-17 拜耳股份有限公司 制造药物递送装置的方法和根据该方法制成的药物递送装置
WO2017173044A1 (en) 2016-04-01 2017-10-05 Therapeuticsmd Inc. Steroid hormone compositions in medium chain oils
WO2017173071A1 (en) 2016-04-01 2017-10-05 Therapeuticsmd, Inc. Steroid hormone pharmaceutical composition
GB201614179D0 (en) * 2016-08-19 2016-10-05 Mereo Biopharma 2 Ltd Dosage regimen for the treatment of endometriosis
CN109248166A (zh) * 2017-07-13 2019-01-22 国家卫生计生委科学技术研究所 阿那曲唑储库型阴道环的制备及应用
US10918649B2 (en) 2019-06-21 2021-02-16 The Population Council, Inc. System for providing birth control
US20240122885A1 (en) * 2021-02-12 2024-04-18 The Regents Of The University Of California Endometriosis-Related Methods and Compositions
CA3251695A1 (en) * 2022-02-22 2023-08-31 Celanese Eva Performance Polymers Llc Intravaginal ring device for the administration of an aromatase inhibitor
CN115804762B (zh) * 2022-12-20 2024-05-31 浙江大学 一种巨噬细胞膜包覆的异位子宫内膜靶向纳米粒、制备方法及应用

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8517360D0 (en) * 1985-07-09 1985-08-14 Erba Farmitalia Substituted androsta-1,4-diene-3,17-diones
JP2602456B2 (ja) * 1990-04-12 1997-04-23 雪印乳業株式会社 子宮内膜症治療剤
FI95768C (fi) * 1993-06-17 1996-03-25 Leiras Oy Emättimensisäinen antosysteemi
US7744916B2 (en) * 1997-06-11 2010-06-29 Umd, Inc. Coated vaginal device for delivery of anti-migraine and anti-nausea drugs
FI20000572A7 (fi) * 2000-03-13 2001-09-14 Schering Oy Implantaattien asettamiseen tarkoitettu laite
MXPA03006607A (es) * 2001-01-26 2003-09-22 Upjohn Co Metodo combinado para tratar trastornos dependientes de hormonas.
GB0120147D0 (en) * 2001-08-17 2001-10-10 Metris Therapeutics Ltd Treatment method
WO2003017973A1 (en) 2001-08-31 2003-03-06 Pantarhei Bioscience B.V. A method of treating benign gynaecological disorders and a drug delivery vehicle for use in such a method
GB0302572D0 (en) 2003-02-05 2003-03-12 Astrazeneca Ab Method of treatment
GB0320238D0 (en) * 2003-08-29 2003-10-01 Medical Res Council Treatment of disease
US20050101579A1 (en) * 2003-11-06 2005-05-12 Shippen Eugene R. Endometriosis treatment protocol
TW200930343A (en) * 2007-09-21 2009-07-16 Organon Nv Drug delivery system
TW200927141A (en) * 2007-11-22 2009-07-01 Bayer Schering Pharma Oy Vaginal delivery system
US20110033519A1 (en) * 2009-08-07 2011-02-10 Leong Madeline Device with Aromatase Inhibitor for the Treatment and Prevention of Uterine Fibroids and Method of Use

Also Published As

Publication number Publication date
SG184111A1 (en) 2012-10-30
US20150359802A1 (en) 2015-12-17
BR112012024739A2 (pt) 2016-06-07
DK2552404T3 (en) 2015-03-30
WO2011120925A1 (de) 2011-10-06
HRP20150294T1 (hr) 2015-06-19
ES2533101T3 (es) 2015-04-07
CA2794790A1 (en) 2011-10-06
PT2552404E (pt) 2015-03-30
EP2552404A1 (de) 2013-02-06
AU2011234587A1 (en) 2012-10-25
US20130131027A1 (en) 2013-05-23
EA201201358A1 (ru) 2013-04-30
CN103002873B (zh) 2015-02-18
MA34099B1 (fr) 2013-03-05
PE20130524A1 (es) 2013-04-26
ECSP12012176A (es) 2012-10-30
CU20120145A7 (es) 2013-05-31
ME02159B (me) 2015-10-20
CL2012002722A1 (es) 2013-01-18
DOP2012000255A (es) 2013-04-30
JP2013523683A (ja) 2013-06-17
HK1179531A1 (en) 2013-10-04
IL222056A (en) 2016-03-31
TN2012000468A1 (en) 2014-01-30
JP6012048B2 (ja) 2016-10-25
CO6630125A2 (es) 2013-03-01
MY160353A (en) 2017-02-28
AR080861A1 (es) 2012-05-16
MX2012011329A (es) 2012-11-30
TW201632184A (zh) 2016-09-16
CR20120493A (es) 2012-11-22
EA025582B1 (ru) 2017-01-30
PL2552404T3 (pl) 2015-05-29
CN103002873A (zh) 2013-03-27
GT201200267A (es) 2014-06-04
CY1116187T1 (el) 2017-02-08
NZ602698A (en) 2014-08-29
TW201201799A (en) 2012-01-16
ZA201206869B (en) 2016-01-27
JP2016164200A (ja) 2016-09-08
EP2552404B1 (de) 2015-01-21
UY33303A (es) 2011-10-31
AU2011234587B2 (en) 2015-07-09
SI2552404T1 (sl) 2015-04-30
DE102010003494A1 (de) 2011-10-06
RS53876B1 (sr) 2015-08-31
UA109655C2 (uk) 2015-09-25
KR20130010047A (ko) 2013-01-24
TWI576107B (zh) 2017-04-01

Similar Documents

Publication Publication Date Title
PH12012501944A1 (en) Parenteral pharmaceutical form which releases aromatse inhibitors and gestagens, for the treatment of endometriosis
JO3732B1 (ar) مشتقات 17-هيدروكسي-17بنتافلوروإيثيل-إسترا-4،9(10)-دين-11-أريل، طريقة لإنتاجها واستخدامها في معالجة الأمراض
MX2022001251A (es) Composiciones y metodos para reducir eventos adversos cardiovasculares graves.
MX2018007354A (es) Formulaciones y metodos para controlar el ciclo reproductivo y la ovulacion.
MX370250B (es) Dispositivo de estabilizacion cervical.
MY181349A (en) Oxytocin receptor antagonist therapy in the luteal phase for implantation and pregnancy in women undergoing assisted reproductive technologies
PH12017502100A1 (en) Selective progesterone receptor modulator (sprm) regimen
Garcia et al. Mucosal immunity in the human female reproductive tract
MX363979B (es) Forma de dosificacion de un antagonista del receptor de progesterona.
TH133904A (th) รูปแบบยาที่ไม่ผ่านทางเดินซึ่งปลดปล่อยสารยับยั้งอะโรมาเทสและเจสตาเจนเพื่อรักษาภาวะเยื่อบุมดลูกเจริญผิดที่
UA108148C2 (uk) Спосіб консервативного лікування істміко-цервікальної недостатності
MX2014012848A (es) Uso de 18-metil-15b,16b-metilen-19-nor-20-espirox-4-en-3-onas en el tratamiento de menorragia, y sistemas intrauterinos que comprenden 18-metil-15b,16b-metilen-19-nor-20-espirox-4-en-3-onas para el tratamiento de trastornos con sangrado uterino.
MX2014012849A (es) USO INTRAUTERINO DE 18-METIL-15ß,16ß-METILEN-19-NOR-20-ESPIROX-4-E N-3-ONAS, SISTEMAS INTRAUTERINOS QUE CONTIENEN 18-METIL-15ß,16ß-METILEN-19-NOR-20-ESPIROX-4-EN-3-ONAS, ASI COMO SU USO EN LA ANTICONCEPCION Y TERAPIA GINECOLOGICA.
UA73187U (ru) Способ лечения женщин с вторичной плацентарной дисфункцией на поздних сроках беременности
UA35393U (ru) Способ реабилитации репродуктивной функции после органосберегающих операций по поводу трубной беременности
UA90664U (uk) Спосіб лікування корів з післяродовим метритом та гнійно-нектротичними ураженнями в ділянці пальців
UA99532U (uk) Спосіб підвищення запліднюваності кобил проведенням санації внутрішніх статевих органів
PH12016000065E1 (en) Insert (preventive family planning tool and method)
UA85891U (ru) Способ лечения гиперпролиферативных состояний органов малого таза
UA67587U (ru) Способ лечения псевдоэрозий шейки матки у женщин
UA100789U (uk) Спосіб лікування пацієнток з аномальними матковими кровотечами на тлі антикоагуляційної терапії
UA112315C2 (uk) Внутрішньоматкові системи, пристрої введення пристроїв iud (внутрішньоматкових пристроїв) і пов'язані з ними способи і набори
UA47984U (ru) Способ лечения тубоовариальных образований воспалительного генеза
UA68329U (ru) Способ лютеинизации геморрагических фолликулов у кобыл